B cell chronic lymphocytic leukemia (CLL) is the malignant, monoclonal equivalent of a human CD5 + B cell. Previous studies have shown that the V. and VL genes rearranged and/or expressed in CLL have few and apparently random mutations. However, in this study, we have found that the rearranged V.251 gene, one of the three-membered V.5 family, has extensive and selective mutations in B-CLL cells. Somatic mutation at the nudeotide level is 6.03% in B-CLLs whereas the somatic mutation levels are much lower in CD5 + and CD5-cord B cells, adult peripheral blood B cells, and Epstein-Barr virus-transformed CD5 + B cell lines (0.45, 0.93, and 1.92%, respectively). Complementary determining region I (CDR1) mutation in CLLs is particularly prevalent, and interchanges in CDRs often lead to acquisition of charge. Analysis of somatic mutations and mutations to charged residues demonstrated that the mutations in CLLs are highly selected.
I
n the human, the estimated 100-200 VH gene segments on chromosome 14 can be divided into six families based on nucleotide sequence homology (for review see reference 1). Family size ranges from greater than 25 (V.3 and V.1) to one (V.6), with the "smaller" families (V.4, V.5, and V.6) displaying unexpectedly low polymorphism (2) . We discovered the V.5 family in a case of familial B cell chronic lymphocytic leukemia (B-CLL) 1 (3) and demonstrated that one (V.251) of two functional (V.251 and V.32) and one pseudo (V.15) members is rearranged in about 20% of CLLs examined (4) . Others have shown that the V.3 family is the most commonly used in CLL, in proportion to its relative size, and have confirmed that usage of V.5 and the other small families is biased (5) (6) (7) (8) (9) (10) . Although the V.1 family is underrepresented in CLL with respect to its germline complexity, one member (51P1) is observed in 10% of CLLs and constitutes 60% of the total V.1 contribution (5) . Preferential usage of a VK3b gene and the associated crossreactive idiotype has been observed (11, 12) . In cases where the germline equivalents could be identified, V. usage in CLL often reflects the fetal repertoire; i.e., restricted usage of "developmentally regulated" genes (for review see reference 13) displaying little or no somatic mutation, This is in contrast to the relatively high frequency of V. and VL mutations seen in follicular lymphoma (14) .
1 Abbreviations used in this paper: B-CLL, B cell chronic lymphocytic leukemia; K/S mutation, replacement/silent mutation.
Most B-CLL express CD5, a marker present on <15% of normal PBLs or splenocytes, but present on most cord blood B cells (for review see references 15 and 16) . Human CD5 + B cells, and the correspondingly-1 B subset in mice, appear to constitute a distinct developmental lineage and share important functional similarities. Human and mouse CD5 + B cells produce a disproportionate level of low affinity, polyspecific autoantibodies (15) (16) (17) . It has been proposed (18) that CLL could be a consequence of the unique ontogeny of the Lyl/CD5 lineage in that repertoires become progressively restricted, inevitably leading to monoclonality and clones that eventually transform. As with B-CLL, murine Ly-1 B cells have generally demonstrated restricted (19) if not unique (20) V. repertoires with limited to no somatic mutation (16) .
The prevailing speculation from the above considerations is that Ig genes expressed in CLL lack mutations and encode polyspecific autoreactivity. However, data we present here raise questions as to the generality of that opinion. A prototypic developmentally regulated V.5 gene (V.251) is extensively mutated in most CD5 + B-CLLs in a manner consistent with antigen drive, whereas little, if any, mutation of V.251 is seen in preimmune and postimmune CD5 + or CD5-compartments.
Materials and Methods
Patient Materials and Cells. Frozen CLL lymphocytes were obtained from 40-60-yr-old patients from W. Blattner (Environmental Epidemiology Branch, National Cancer Institute, Frederick, MD), tionated on 1% low-melting agarose gels, ligated into EcoRI and BamHI sites of pUC19, and transformed into CaCh-competent BSJ72 bacteria. All cDNA and PCR-generated clones were sequenced on both strands by the dideoxy chain termination method (27) using the M13 universal and reverse-universal primers. For CLLs, multiple colonies were sequenced. For PBL B cells and cord B cells, clones were randomly chosen and sequenced. Clones with identical mutations or germline sequences were verified as distinct by analysis of their N-D-J segments. Sequencing data were analyzed with DNAstar programs (DNAstar Inc., Madison, WI).
Analysis of Mutations.
All mutations in one set of B cells were evaluated as a pool since each set contains a number of clones (11 in CLLs, 19 in cord B cells, 8 in EBV-transformed B cells, and 13 in PBL B cells). A sensitive binomial probability model used previously by Shlomchik et al. (28) was used to evaluate whether the observed replacement mutations in CDRs were selective. That is, the probability of the number of R mutations in CDRs is: pgco~ = n!/[Rcl~Rl(n-Kcug!)] x pr~CDx X (1 --p),-gcDg; where RcD~ = no. of replacement mutation in CDRs; p = expected probability of K mutations which is the product of the relative size of CDKs and the expected R mutations; and n = total mutation occurred = RcnR + S + 2KrR. The same method was also used to evaluate the frequency of mutations leading to charged residues in CDRs.
Results

VH251 Rearranged in CLL B Cells Are Extensively Mutated
Relative to Cord Blood and Adult PBLs. We screened 40 CLLs and obtained 11 that rearranged V~251, 1 that rearranged V.32 and none that rearranged V.15 (data not shown). This biased percentage is consistent with what we (4) have previously observed. Since the focus here is on V.251 mutation, the PCR reaction used for cloning from the normal B cell population was specific for VH251. We previously showed that there were essentially no differences within V.251 sequences obtained from the livers of 10 adult donors (2) . This lack of polymorphism allows conclusions to be drawn regarding somatic mutation in the absence of individual germline sequences.
Complete nudeotide sequences of rearranged V.251 genes from CLLs, cord blood B cells, CD5 + B cell lines and adult PBL are shown in Figs. 1-4. The 11 CLL sequences derived from individual cDNA libraries (CLLs 1-9) or from PCR amplification of genomic DNA (CLLs 10-11). Genomic Southern analysis performed on CLL samples where adequate DNA was available revealed the V.251 rearrangement at >90% molarity (3, 4 , and data not shown). This agreed with the morphological assignment (20, and see Materials and Methods) of leukemic mass, consistent with previous observations that CLL is macroscopically monoclonal. Regardless of the molecular cloning method, there are extensive somatic mutations in VH251 rearranged in CLLs. In contrast, the somatic mutation of rearranged V.251 in CD5 § or CDScord blood B cells and adult unfractionated PBLs are much lower, whereas a relative high level of mutation occurs in EBVtransformed CD5 + B cell lines. Collectively, the average mutation level (base mutations/total V. bases) of V,251 utilized in CLLs is 6.03%, about 13 and 6.5-fold higher than those in cord blood B cells, and PBLS, respectively (Table 1) . The average mutation level of eight sequences from EBVtransformed CD5 + B cell lines is 1.92%, about twofold greater than in PBL and fourfold greater than in cord blood B calls. These low mutation levels, which include several 100% germline sequences, strongly argue against the possibility that the extensive mutations in CLLs 1-9 resulted from PCR errors.
We previously noted the C to G polymorphism at position 54 in 29% of adults (2, and data not shown). We find the equivalent value in adult PBLs (23%), double that value in unfractionated cord (53%) but none of the 11 CLLs, 8 EBV-transformed CD5 + B cells, nor 4 CD5 + cord sequences carried this polymorphism. Although the database must be expanded, a CD5 +, subset restricted bias is evident. There are no features that distinguish the populations from which these samples were selected.
Lack of Intraclonal Variability. The excessive and unprecedented levels of mutation observed in the V,251 CLL sequences raised the possibility of an ongoing mutational process. We chose two samples (CLLs 2 and 10) whose rear- *****CDRI****** ********************************************* ranged V.251 genes were highly mutated and were molecularly cloned by different methods. Five to six independent sequences obtained from independent bacterial plaques or colonies were identical within 1-2 bases (data not shown). We conclude that as in other CD5 + CLL analyses, intraclonal variability is improbable, suggesting that the observed mutations occurred before the transformation process.
Mutation within V,251 Genes Utilized in CLLs Are Highly Selected. Table I *****CDRI****** ******************************************** *****CDRI****** ********************************************* (Fig. 5) . In CDR1, 54% of the amino acids are replaced, many with charged residues. All six CDR1 residues of germline V,251 are uncharged, whereas 31% of the substituted residues are charged. Serine 31 is a hotspot, with 8/11 sequences substituted at this position. Particularly within CDRs, common mutations were shared among 2-3 sequences. Both conservative and nonconservative changes were observed, the most striking being the neutral to charge conversions at positions 33 (W~R), 67 (G~D), and 78 (S~R). The expected frequency of mutations leading to charged residues in FWRs is 4.6%, but there is a much higher percentage of observed mutations to charged residues in CDRs (23.7%), which is indicative of positive selection. Using the binomial probability model to assess this observation, we obtained ap value of 3.88 x 10 -is, whereas the expected p value is 10 -2. This indicates that a strong selective force is operative in generating charged residues within CDRe. The combined effect of the extensive mutations in CDKs and FWKs leads to a significant increase in overall positive charge.
Discussion
V.251 is a member of the small human V.5 gene family (4) that displays remarkably little polymorphism (2) . That allowed us to compare the nucleotide sequences of the V.251 gene rearranged in different cell populations without the corresponding germline counterparts. 9 of 11 V.251 genes utilized in CLLs have dusters of extensive mutation. Using a binomial probability model, we found that mutations within CDRs of CLLs are highly selective. The selection level is much higher than those observed in the other B cell populations studied here (Tables 1 and 2 ) or in the two previous reports of antigen-specific EBV-transformants (31) or hybridomas (32) that express a V.251 H chain. The deduced amino acid sequences of the CLL were remarkable for the high ratio of CDR replacement with charged residues. The binomial probabilities confirmed that these mutations are also highly selected and occur at much higher than ex-pected frequency. In CDK1, half of the germline neutral residues are replaced, and a third of these replacements are with charged residues. A similar CDK1 focus was observed in the two V.251-utilizing antibodies previously reported (31, 32) . Both had four CDR1 interchanges. All are found among our CLL pool although none are charged.
Several groups have studied VL and V. genes utilized in human CLLs and found little or no mutations (5-11). As with V.251, some of the V. genes analyzed are considered to be developmentally regulated, in that they are overrepresented in the fetal repertoire (13) . There does not appear to be any phenotypic differences among the CLLs analyzed in other studies (5-11) and ours. Within our 11 samples, there were no features that distinguished the two CLLs that expressed V,251 with only a few mutations. In all the studies, sequences were derived exclusively from IgMs. One feature that distinguishes the V.5 family from all other human V. families is that two members (V.215 and V.15) express abundant germline transcripts in CLLs (4, 33) . The correlation between germline transcription and subsequent V to DJ recombination (34) conceivably could be extended to somatic mutation. Mutation of a productively regulated V~ transgene requires its transcription (35) . However, gemaline V.251 transcripts in CLLs are not mutated (33) , nor would one expect the selective mutation pattern we have observed to be generated from an antigen-independent mechanism.
Regardless of why V.251 is susceptible to mutation, the result is at variance with the prevailing view of low affinity, polyspecific antibody expression in CLL. Instead, in the majority of our CLLs, the V.251 sequences appear to be derived from prototypic high affinity antibodies. Selection could occur after the malignant transformation event. A model for B cell receptor (surface Ig idiotype)-mediated leukemogenesis, first elaborated by McGrath et al. (36) and potentially relevant to our situation, was provided by Mann et al. (37) . In their analysis of B-CLL in HTLV-I endemic Caribbeans, a heterohybrid of one B-CLL demonstrated strict specificity for the gag 41 surface protein of HTLV-I. Inconsistent with this model is our lack of intraclonal sequence variability. Also we found no correlation of V. usage with that of Vx3b (or any other L chain), nor with that of D. segment. This puts unprecedented requirements on V. sequence/variation. We favor the alternative model that mutation precedes transformation. We envisage two general categories of CD5 § B cells: those that do not somatically mutate and those that do. The latter are the precursor lineage for most of the V,251-utilizing CLL (with CLL being an exception) and potentially may carry additional biases, such as J. preference.
The antigen drive apparently operative on V~251 may derive from self-reactivity. Most human autoantibodies are produced by CD5 + B cells that preferentially use small V, families (15) (16) (17) . Although not the rule with IgMs, extensively mutated sequences have been served in some autoantibodies (38) (39) (40) . The unusual acquisition of charged residues we observed is reminiscent of high affinity antinucleic acid responses (41) . Some CD5 + B cells expressing V,251 may be stimulated and selected by self-antigens to proliferate constantly, subjecting these cells to abnormal expansion and eventual transformation into tumors. Alternatively, our data is equally compatible with a foreign antigen providing the drive.
The potential for V.251 diversification in the normal preimmune environment is extremely limited, irrespective of the CD5 +/CDS-compartment. That V,251 in adult EBVtransformed CD5 § cells show relative high mutation extends findings that human CD5 + cells are susceptible to an antigen-driven diversification mechanism (31, (38) (39) (40) . As with limited germline polymorphism, absence of mutation could be an advantage for a developmentally regulated V. gene. In the case of V.251 expressers, CLL could be a natural consequence of repertoire restriction via expansion of given clones by a "super" antigen. Thus the normal inability to develop this high affinity response would divert the inevitable disaster of monoclonality.
